Private Market View

Changcheng Pharmaceutical

Changchun, China · Founded 2016 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Changxing Fund, Jilin Province Technology Investment Fund.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Changcheng Pharmaceutical
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Changcheng Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Changcheng Pharmaceutical

Manufacturer of prodrug therapies designed to reduce side effects and improve drug delivery. The company offers a research-driven prodrug development platform focused on multiple tumour cancers, enabling patients to access effective therapies with improved tolerability and practical administration.

Sector
Healthcare
HQ
Changchun, China
Founded
2016
Ownership
Privately Held (backing)
PA Mark — not yet priced

Changcheng Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Changcheng Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Changcheng Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.